Xconomy: Affymax News, Articles and Opinions

“affymax” Archives

Entry	Author	Date	Location
After Rival Stumbles, Relypsa Gets $1.5B Buyout Bid From Galenica	Ben Fidler	07/21/16	San Francisco
Syndax Cuts Price But Bags $53M in Second IPO Try	Ben Fidler	03/02/16	Boston
As Rival Sputters, FibroGen Heads to Nasdaq Via $146M IPO	Ben Fidler	11/14/14	San Francisco
West Coast Biotech Roundup: Affymax, K2, Roche/Stratos, & More	Alex Lash	06/26/14	San Francisco
Affymax Cuts 230 Jobs, Mulls Bankruptcy, After Drug Withdrawal	Luke Timmerman	03/18/13	San Francisco
Has The Pendulum Swung Too Far in Favor of Rare Diseases?	Stewart Lyman	03/14/13	Seattle
Some Bold Baseball and Biotech Picks for the 2013 Season	Luke Timmerman	03/11/13	National
Affymax, Takeda Win Approval of Anemia Drug to Challenge Amgen	Luke Timmerman	03/27/12	San Francisco
Some Tongue-in-Cheek Fantasy Baseball (and Biotech) Picks	Luke Timmerman	03/26/12	National
Affymax Prepares to Mount Challenge to Amgen Anemia Drug Monopoly	Luke Timmerman	01/25/12	San Francisco
Affymax Passes FDA Panel Scrutiny, Looks to Challenge Amgen Anemia Drug	Luke Timmerman	12/07/11	San Francisco
Affymax Shares Climb As FDA Considers Wider Use for Anemia Drug	Luke Timmerman	12/05/11	San Francisco
Affymax Gears Up for its Make-or-Break Moment, As Anemia Drug Faces FDA Scrutiny	Luke Timmerman	11/17/11	San Francisco
FDA Says It Will Review Affymax Drug	Luke Timmerman	07/27/11	San Francisco
SV Feels Lonely at the Top, Canaan Finds Biotech Groove, Portola Gets Drug Back, & More in Bay Area Life Sciences News	Luke Timmerman	03/25/11	San Francisco
Affymax Raises $50M	Luke Timmerman	03/18/11	San Francisco
E-Commerce Pioneer Sets Up Cancer Commons, Affymax Hires New Boss, Plexxikon Opts In, & More Bay Area Life Sciences News	Luke Timmerman	01/07/11	San Francisco
Affymax Hires New CEO, Former Genentecher, to Complete FDA Push With Anemia Drug	Luke Timmerman	01/06/11	San Francisco
Codexis Morphs From Big Science Project Into $100M Business	Luke Timmerman	10/27/10	San Francisco
Edmund Shea Jr. Dies at 80	Wade Roush	08/16/10	San Francisco
Affymax Isn’t Dead Yet, ZeaChem Pursues Wood Chip Ethanol, Third Rock Heads West, & More Bay Area Life Sciences News	Luke Timmerman	08/13/10	San Francisco
Nuon Adds $10M Debt, Options	Luke Timmerman	08/12/10	San Francisco
Affymax Lives to Fight Another Day, In Bid to Challenge Amgen’s Monopoly	Luke Timmerman	08/09/10	San Francisco
Genentech’s Souped-Up Antibody, Reg Kelly’s Mission, LS9 Nears Moment of Truth & More Bay Area Life Sciences News	Luke Timmerman	06/25/10	San Francisco
Affymax Tanks on Anemia Results	Luke Timmerman	06/21/10	San Francisco
San Diego’s Palkion Chases Amgen’s Big Market, Joins Race to Develop Oral Anemia Drug	Luke Timmerman	09/01/09	San Diego
Page 1 of 1

Underwriters and Partners

Xpertise: Watch + Learn

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

Xconomy Insight · Webinar
The New Era of Emerging Therapies Webinar Series
Potential cures and treatments for diseases are on the horizon for a growing number of patients, thanks to recent breakthroughs in CRISPR gene-editing technologies and in cell and gene therapy.

Sponsored · Whitepaper
Monitoring Solutions for Pharma-CRO/CMO Partnerships to Maintain Quality & Timelines
Implementing electronic solutions for risk mitigation
XiltriX